CCK-8 assay was used to compare the therapeutic effect of the supernatants of UCMSCs-Tandab(IL-6/CD20) against lymphoma cells with rituximab, tocilizumab and rituximab + tocilizumab in vitro. The gene discussed is IL6; the disease is lymphoma.